Boston Scientific Corp (BSX)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | 1,850,000 | 1,789,000 | 1,825,000 | 1,771,000 | 1,593,000 | 1,228,000 | 898,000 | 874,000 | 656,000 | 598,000 | 829,000 | 755,000 | 986,000 | 1,056,000 | 496,000 | 177,000 | -139,000 | 3,705,000 | 3,986,000 | 4,287,000 |
| Total stockholders’ equity | US$ in thousands | 21,770,000 | 20,708,000 | 20,371,000 | 19,925,000 | 19,281,000 | 18,885,000 | 18,226,000 | 17,850,000 | 17,574,000 | 17,641,000 | 17,252,000 | 16,735,000 | 16,623,000 | 16,461,000 | 15,942,000 | 15,720,000 | 15,327,000 | 15,564,000 | 15,616,000 | 13,804,000 |
| ROE | 8.50% | 8.64% | 8.96% | 8.89% | 8.26% | 6.50% | 4.93% | 4.90% | 3.73% | 3.39% | 4.81% | 4.51% | 5.93% | 6.42% | 3.11% | 1.13% | -0.91% | 23.80% | 25.53% | 31.06% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $1,850,000K ÷ $21,770,000K
= 8.50%
The return on equity (ROE) of Boston Scientific Corp has shown some fluctuations over the periods provided. From March 31, 2020, to June 30, 2020, the company experienced a decrease in ROE from 31.06% to 25.53%. This decline continued in the following quarters, reaching a low of -0.91% by December 31, 2020.
However, the company's ROE started to recover in the subsequent periods, reaching positive territory with 1.13% by March 31, 2021, and showing a steady increase throughout the rest of 2021. By December 31, 2021, the ROE had improved to 5.93%.
In 2022, the ROE continued to demonstrate a gradual increase, albeit at a slower pace compared to the previous year. By the end of 2022, the ROE stood at 3.73%. The positive trend persisted into 2023 and 2024, with ROE reaching 8.50% by December 31, 2024.
Overall, the analysis suggests that Boston Scientific Corp managed to overcome the challenging period in 2020 and successfully improved its ROE performance in the subsequent years, showcasing a positive upward trend in profitability and efficiency in the utilization of shareholder equity. However, the company should continue to monitor and assess its ROE to ensure sustained financial health and value creation for shareholders.
Peer comparison
Dec 31, 2024
See also:
Boston Scientific Corp Return on Equity (ROE) (Quarterly Data)